Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.

@article{Herzmann2005SafetyPA,
  title={Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-na{\"i}ve human immunodeficiency virus-infected patients.},
  author={Christian Herzmann and Keikawus Arast{\'e}h and R. L. Murphy and Hubert Schulbin and Peter Kreckel and D Drauz and Raymond F Schinazi and Amanda Beard and Leanne Cartee and Michael J. Otto},
  journal={Antimicrobial agents and chemotherapy},
  year={2005},
  volume={49 7},
  pages={2828-33}
}
Racivir [RCV; (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine], a 50:50 racemic mixture of the two beta nucleoside enantiomers, is currently in development for the treatment of human immunodeficiency virus type 1 (HIV-1) infections. RCV was administered once a day orally for 14 days at doses of 200, 400, or 600 mg in combination with stavudine and efavirenz to HIV-1-infected treatment-naïve male volunteers in a phase Ib/IIa study. Six volunteers at each dose were monitored for a total of 35… CONTINUE READING